{"id":137334,"date":"2026-01-15T17:20:13","date_gmt":"2026-01-15T17:20:13","guid":{"rendered":"https:\/\/www.europesays.com\/se\/137334\/"},"modified":"2026-01-15T17:20:13","modified_gmt":"2026-01-15T17:20:13","slug":"novo-nordisk-och-eli-lilly-stams-i-usa-bn","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/137334\/","title":{"rendered":"Novo Nordisk och Eli Lilly st\u00e4ms i USA &#8211; BN"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Strive Compounding Pharmacy har l\u00e4mnat in en st\u00e4mning mot Eli Lilly och Novo Nordisk i USA. Apoteket anklagar bolagen f\u00f6r att ha f\u00f6rs\u00f6kt h\u00e4mma konkurrensen och begr\u00e4nsa patienters tillg\u00e5ng till GLP-1-l\u00e4kemedel, rapporterar Bloomberg News.\n <\/p>\n<p>Enligt st\u00e4mningen ska l\u00e4kemedelsbolagen ha utnyttjat sina marknadspositioner f\u00f6r att motverka f\u00f6rskrivning och anv\u00e4ndning av alternativa GLP-1-preparat.\n <\/p>\n<p>M\u00e5let har l\u00e4mnats in i en federal domstol i Texas.<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Reno Santic<br \/>\n <br class=\"col-start-2\"\/><br \/>\n Nyhetsbyr\u00e5n Finwire<br \/>\n <br class=\"col-start-2\"\/><br \/>\n <a class=\"twitter-timeline\" data-width=\"1200\" data-height=\"1000\" data-dnt=\"true\" href=\"https:\/\/twitter.com\/Finwire?ref_src=twsrc%5Etfw\" rel=\"nofollow noopener\" target=\"_blank\">Tweets by Finwire<\/a><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><br \/>\n <br class=\"col-start-2\"\/><br \/>\n newsroom@finwire.se<\/p>\n<p><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n","protected":false},"excerpt":{"rendered":"Strive Compounding Pharmacy har l\u00e4mnat in en st\u00e4mning mot Eli Lilly och Novo Nordisk i USA. Apoteket anklagar&hellip;\n","protected":false},"author":2,"featured_media":119816,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[72,70,71,34,31,33,32,30],"class_list":{"0":"post-137334","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ekonomi","8":"tag-business","9":"tag-economy","10":"tag-ekonomi","11":"tag-se","12":"tag-svenska","13":"tag-sverige","14":"tag-sweden","15":"tag-swedish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115900266738904997","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/137334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=137334"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/137334\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/119816"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=137334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=137334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=137334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}